What are Supernus Pharmaceuticals's profit margins?

Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.

Where does Supernus Pharmaceuticals's income statement data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Supernus Pharmaceuticals SUPN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$718.95M+8.6%	$661.82M+8.9%	$607.52M-8.9%	$667.24M+15.1%
Total cost of revenue	$74.56M-4.3%	$77.91M-7.0%	$83.78M-3.9%	$87.22M+16.2%
Gross profit	$644.39M+10.4%	$583.91M+11.5%	$523.74M-9.7%	$580.02M+14.9%
Gross margin	89.6%+1.4pp	88.2%+2.0pp	86.2%-0.7pp	86.9%-0.1pp
Research and development	$106.24M-2.4%	$108.8M+18.8%	$91.59M+22.9%	$74.55M-17.6%
Selling, general and administrative	$485.56M+51.0%	$321.58M-4.4%	$336.36M-10.8%	$377.22M+23.8%
Compensation and benefits	——	——	——	——
Advertising	——	——	——	——
Depreciation and amortization	$90.05M+15.5%	$77.98M-5.4%	$82.39M-0.3%	$82.63M+176%
Impairment charges	$0—	$0—	——	$0—
Total costs & expenses	$781.24M+34.7%	$580.15M-5.3%	$612.79M-1.3%	$621.11M+25.8%
Operating income	-$62.28M-176%	$81.67M+1,650%	-$5.27M-111%	$46.12M-46.4%
Operating margin	-8.7%-21.0pp	12.3%+13.2pp	-0.9%-7.8pp	6.9%-7.9pp
Other income (expense), net	$13.25M-18.2%	$16.2M+102%	$8.04M-45.0%	$14.62M+214%
Net investment gains (losses)	——	——	——	——
Income before income taxes	-$49.03M-150%	$97.87M+3,434%	$2.77M-95.4%	$60.74M-17.0%
Income tax expense	——	$24.01M—	——	$32K-99.8%
Net income	-$38.55M-152%	$73.87M+5,513%	$1.32M-97.8%	$60.71M+13.6%
Net margin	-5.4%-16.5pp	11.2%+10.9pp	0.2%-8.9pp	9.1%-0.1pp
Diluted earnings per share	-$0.68-152%	$1.32+7,609,281,930,405,189,000%	-$0.00-100%	$1.02+4.1%
Basic earnings per share	-$0.68-151%	$1.34+6,600%	$0.02-98.2%	$1.13+10.8%
Weighted-average shares, diluted	225.5M+1.0%	223.3M-1.7%	227.1M-5.2%	239.5M+10.1%
Weighted-average shares, basic	224.9M+2.2%	220M+0.9%	218M+1.8%	214.2M+0.9%
Share-based compensation expense related to employee stock plans	——	——	——	——
Advertising costs	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——
Amortization of capitalized software and acquired intangible assets	$89.46M+14.7%	$77.98M-5.4%	$82.39M-0.3%	$82.63M+176%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	$25.42M+493%	-$6.47M-326%	-$1.52M-197%	-$510K—
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——
Prior year sale adjustments, percentage	——	——	——	——
Credit losses on securities without previous credit losses	$0—	——	——	——
Total net securities (losses)	——	$9K—	$0—	——
Deferred taxes	$5.21M+126%	-$20.14M+21.7%	-$25.71M+2.3%	-$26.32M—
Effective tax rates	——	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings	——	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements	——	——	——	——
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification	——	——	——	——
Goodwill activity from Sage Acquisition	$7.86M—	——	——	——
Income Taxes Paid, Net	$16.05M-69.9%	$53.25M+45.5%	$36.6M+126%	$16.2M-35.7%
Accounts payable and other current liabilities	-$24.57M-63.6%	-$15.02M+58.6%	-$36.29M-89.4%	-$19.16M-205%
Increase (Decrease) in Accounts Receivable	$22.3M+1,173%	-$2.08M—	——	$16.37M—
Accrued product returns and rebates	——	——	——	——
Increase (Decrease) in Inventories	$7.5M+147%	-$15.81M-159%	-$6.11M-134%	$17.86M+22.5%
Increase (Decrease) in Prepaid Expense and Other Assets	$13.18M-34.4%	$20.08M—	——	-$12.3M—
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	——	——
Insurance Recoveries	——	——	——	——
Inventory Write Down	——	——	——	——
(Amortization) accretion on investments	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$9.13M-25.1%	$12.19M+103%	-$398.97M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	-$189.87M—	——	-$216.66M—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	——	$171.95M—	——	$116.83M-11.0%
Number of commercial products	——	——	——	——
Number of operating segments	——	——	——	——
Number of reportable segments	——	——	——	——
Operating lease right-of-use assets amortization expense	——	$5.45M-16.2%	$6.5M—	——
Other comprehensive income/(loss)	——	——	——	——
Net unrealized gains (losses) on securities still held	——	——	——	——
Other Noncash Income (Expense)	——	——	$606K—	——
Other income, net (Note 6)	$13.25M-18.2%	$16.2M+55.0%	$10.45M-51.8%	$21.69M+269%
Payment for Contingent Consideration Liability, Financing Activities	$24.26M—	$0—	$0—	——
Payment for Contingent Consideration Liability, Operating Activities	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$4.23M+55.8%	$2.72M+36.4%	$1.99M—	$0—
Payments to Acquire Debt Securities, Available-for-Sale	$475.94M-30.8%	$688.01M+577%	$101.62M-75.0%	$406.99M+30.6%
Payments to Acquire Property, Plant, and Equipment	$1.34M+84.6%	$725K+23.5%	$587K—	——
Proceeds from Issuance of Common Stock	$37.62M+152%	$14.91M+126%	$6.61M-46.8%	$12.42M+75.1%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$774.48M+55.2%	$498.87M—	——	$190.74M—
Collaboration revenue, percentage	——	——	——	——
Revenue From Contract With Customer Excluding Assessed Tax	$718.95M+8.6%	$661.82M+8.9%	$607.52M-8.9%	$667.24M+15.1%
Stock-based compensation	$33.05M+19.1%	$27.76M+3.7%	$26.76M+52.3%	$17.57M-1.9%
Granted (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——
Options canceled (in dollars per share)	——	——	——	——
Granted (in shares)	——	——	——	——
Exercised (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——	——	——	——
EBIT	-$62.28M-176%	$81.67M+1,650%	-$5.27M-111%	$46.12M-46.4%
EBITDA	$29.28M-81.9%	$162.08M+104%	$79.59M-39.6%	$131.67M+11.0%
EBITDA	$29.28M-81.9%	$162.08M+104%	$79.59M-39.6%	$131.67M+11.0%
EBITDA margin	4.1%-20.4pp	24.5%+11.4pp	13.1%-6.6pp	19.7%-0.7pp
EBIT	-$62.28M-176%	$81.67M+1,650%	-$5.27M-111%	$46.12M-46.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Supernus Pharmaceuticals's profit margins?: Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
Where does Supernus Pharmaceuticals's income statement data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.